239 related articles for article (PubMed ID: 31935898)
21. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer.
Kaas R; Verhoef S; Wesseling J; Rookus MA; Oldenburg HS; Peeters MJ; Rutgers EJ
Ann Surg; 2010 Mar; 251(3):488-92. PubMed ID: 20134318
[TBL] [Abstract][Full Text] [Related]
22. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis.
Heemskerk-Gerritsen BA; Rookus MA; Aalfs CM; Ausems MG; Collée JM; Jansen L; Kets CM; Keymeulen KB; Koppert LB; Meijers-Heijboer HE; Mooij TM; Tollenaar RA; Vasen HF; ; Hooning MJ; Seynaeve C
Int J Cancer; 2015 Feb; 136(3):668-77. PubMed ID: 24947112
[TBL] [Abstract][Full Text] [Related]
23. Bilateral breast cancers.
Narod SA
Nat Rev Clin Oncol; 2014 Mar; 11(3):157-66. PubMed ID: 24492834
[TBL] [Abstract][Full Text] [Related]
24. Breast cancer in women at high risk: the role of rapid genetic testing for BRCA1 and -2 mutations and the consequences for treatment strategies.
Francken AB; Schouten PC; Bleiker EM; Linn SC; Rutgers EJ
Breast; 2013 Oct; 22(5):561-8. PubMed ID: 23972475
[TBL] [Abstract][Full Text] [Related]
25. Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).
Kiely BE; Jenkins MA; McKinley JM; Friedlander ML; Weideman P; Milne RL; McLachlan SA; Hopper JL; Phillips KA
Breast Cancer Res Treat; 2010 Apr; 120(3):715-23. PubMed ID: 19669874
[TBL] [Abstract][Full Text] [Related]
26. Breast cancer risk perception among women who have undergone prophylactic bilateral mastectomy.
Metcalfe KA; Narod SA
J Natl Cancer Inst; 2002 Oct; 94(20):1564-9. PubMed ID: 12381709
[TBL] [Abstract][Full Text] [Related]
27. Mastectomy for risk reduction or symmetry in women without high risk gene mutation: A review.
Kenny R; Reed M; Subramanian A
Int J Surg; 2018 Feb; 50():60-64. PubMed ID: 29288115
[TBL] [Abstract][Full Text] [Related]
28. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Metcalfe K; Lynch HT; Ghadirian P; Tung N; Olivotto I; Warner E; Olopade OI; Eisen A; Weber B; McLennan J; Sun P; Foulkes WD; Narod SA
J Clin Oncol; 2004 Jun; 22(12):2328-35. PubMed ID: 15197194
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer.
McDonnell SK; Schaid DJ; Myers JL; Grant CS; Donohue JH; Woods JE; Frost MH; Johnson JL; Sitta DL; Slezak JM; Crotty TB; Jenkins RB; Sellers TA; Hartmann LC
J Clin Oncol; 2001 Oct; 19(19):3938-43. PubMed ID: 11579114
[TBL] [Abstract][Full Text] [Related]
30. The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer.
Narod SA
Breast Cancer Res Treat; 2011 Jul; 128(2):581-3. PubMed ID: 21455666
[TBL] [Abstract][Full Text] [Related]
31. Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer.
Evron E; Ben-David AM; Goldberg H; Fried G; Kaufman B; Catane R; Pfeffer MR; Geffen DB; Chernobelsky P; Karni T; Abdah-Bortnyak R; Rosengarten O; Matceyevsky D; Inbar M; Kuten A; Corn BW
Ann Oncol; 2019 Mar; 30(3):412-417. PubMed ID: 30475942
[TBL] [Abstract][Full Text] [Related]
32. What made her give up her breasts: a qualitative study on decisional considerations for contralateral prophylactic mastectomy among breast cancer survivors undergoing BRCA1/2 genetic testing.
Kwong A; Chu AT
Asian Pac J Cancer Prev; 2012; 13(5):2241-7. PubMed ID: 22901201
[TBL] [Abstract][Full Text] [Related]
33. Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancer.
Hamilton JG; Genoff MC; Salerno M; Amoroso K; Boyar SR; Sheehan M; Fleischut MH; Siegel B; Arnold AG; Salo-Mullen EE; Hay JL; Offit K; Robson ME
Breast Cancer Res Treat; 2017 Apr; 162(2):297-306. PubMed ID: 28150129
[TBL] [Abstract][Full Text] [Related]
34. Impact of Prophylactic Mastectomy in BRCA1/2 Mutation Carriers.
Rhiem K; Schmutzler R
Breast Care (Basel); 2014 Dec; 9(6):385-9. PubMed ID: 25759620
[TBL] [Abstract][Full Text] [Related]
35. Oncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With BRCA Mutations: A Multi-institutional Study.
Jakub JW; Peled AW; Gray RJ; Greenup RA; Kiluk JV; Sacchini V; McLaughlin SA; Tchou JC; Vierkant RA; Degnim AC; Willey S
JAMA Surg; 2018 Feb; 153(2):123-129. PubMed ID: 28903167
[TBL] [Abstract][Full Text] [Related]
36. Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer.
Foretová L; Navrátilová M; Svoboda M; Vašíčková P; Sťahlová EH; Házová J; Kleiblová P; Kleibl Z; Macháčková E; Palácová M; Petráková K
Klin Onkol; 2019; 32(Supplementum2):6-13. PubMed ID: 31409076
[TBL] [Abstract][Full Text] [Related]
37. Contralateral Prophylactic Mastectomy: Challenging Considerations for the Surgeon.
Angelos P; Bedrosian I; Euhus DM; Herrmann VM; Katz SJ; Pusic A
Ann Surg Oncol; 2015 Oct; 22(10):3208-12. PubMed ID: 26259752
[TBL] [Abstract][Full Text] [Related]
38. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A;
Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006
[TBL] [Abstract][Full Text] [Related]
39. Risk of Contralateral Breast Cancer in Women with and without Pathogenic Variants in
Hyder Z; Harkness EF; Woodward ER; Bowers NL; Pereira M; Wallace AJ; Howell SJ; Howell A; Lalloo F; Newman WG; Smith MJ; Evans DG
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32045981
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
